Internal Medicine & Geriatrics

Medicine & Life Sciences

1. Tuberculosis 100%
2. Alzheimer Disease 46%
3. Mycobacterium tuberculosis 38%
4. rifapentine 29%
5. Lovastatin 25%
6. HIV 23%
7. Isoniazid 22%
8. Therapeutics 21%
9. Directly Observed Therapy 21%
10. Latent Tuberculosis 21%
11. Cognitive Dysfunction 20%
12. Dementia 19%
13. Air 19%
14. Coronary Artery Disease 19%
15. LDL Cholesterol 19%
16. Pulmonary Tuberculosis 17%
17. T-Lymphocytes 16%
18. Cholesterol 16%
19. Geriatrics 14%
20. Mexican Americans 14%
21. HDL Cholesterol 14%
22. Tuberculin Test 14%
23. Tuberculin 12%
24. Gemfibrozil 12%
25. alirocumab 12%
26. Primary Prevention 11%
27. Biomarkers 11%
28. Elderly 11%
29. Skin Tests 11%
30. Education 11%
31. Costs and Cost Analysis 10%
32. Multidrug-Resistant Tuberculosis 10%
33. Lipids 10%
34. Population 10%
35. Lung 9%
36. Students 9%
37. Interleukin-18 9%
38. Interferons 9%
39. Hypoxia 9%
40. Placebos 8%
41. Hydroxymethylglutaryl-CoA Reductase Inhibitors 8%
42. HIV Infections 8%
43. Health 8%
44. Odds Ratio 8%
45. Mycobacterium tuberculosis antigens 8%
46. Serum 8%
47. CD4 Lymphocyte Count 8%
48. Confidence Intervals 8%
49. Pharmaceutical Preparations 8%
50. HIV-1 7%
51. Randomized Controlled Trials 7%
52. Acute Coronary Syndrome 7%
53. Accidental Falls 7%
54. Infections 7%
55. Heart Rate 7%
56. Immunization 6%
57. Health Care Costs 6%
58. Delivery of Health Care 6%
59. Quality Improvement 6%
60. Primary Health Care 6%
61. Recurrence 6%
62. Cyclic AMP Response Element-Binding Protein 6%
63. Canada 6%
64. Child 6%
65. Peptides 5%
66. Immunosuppressive Agents 5%
67. Lipoproteins 5%
68. Vaccination 5%
69. Vascular Dementia 5%
70. Respiration 5%
71. Reperfusion Injury 5%
72. Hospitalization 5%
73. Natural Killer Cells 5%
74. rifamycin SV 5%
75. Rifampin 5%
76. Interleukin-15 5%
77. Monocytes 5%
78. Comparative Physiology 5%
79. Mexico 5%
80. C-Reactive Protein 5%
81. Natural Cytotoxicity Triggering Receptor 1 5%
82. Hispanic Americans 5%